No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Northeast Pharmaceutical Group (000597.SZ): Fangda Steel has not yet started to increase its shareholding in the company.
On March 11, Guolonghui reported that Northeast Pharmaceutical Group (000597.SZ) announced that as of March 11, 2025, the implementation period of this shareholding plan has passed the halfway mark. Due to self-coordination and other factors, Fangda Steel has not yet begun shareholding in the company's stocks. Since the shareholding plan has not been fully implemented, Fangda Steel will implement the aforementioned shareholding plan at an opportune time during the implementation period.
Northeast Pharmaceutical Gets Nod to Market HIV Raw Drug Material
Northeast Pharmaceutical Group (000597.SZ): The上市申请 for the Active Pharmaceutical Ingredient Efevren has been approved.
On February 14, Gelonghui reported that Northeast Pharmaceutical Group (000597.SZ) announced that it recently received the "Approval Notice for the Listing Application of Efavirenz" (Registration Number: Y20230001004, Acceptance Number: CYHS2360797, Notice Number: 2025YS00115) issued by the National Medical Products Administration. Efavirenz is a key drug for the treatment of human immunodeficiency virus infection and is a selective non-nucleoside reverse transcriptase inhibitor for human immunodeficiency virus type 1 (HIV-1). Efavirenz is for HIV-1 reverse transcriptase.
Northeast Pharmaceutical Group Co., Ltd.'s (SZSE:000597) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Northeast Pharmaceutical Group Names Chair
